Kymera Therapeutics: Funding, Investors & Team (Oct 2026)
Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation. It features a proprietary predictive modeling degradation platform with a novel small molecule modality to accelerate the drug discovery designed for disease-causing proteins.
Kymera Therapeutics has raised $854M across 3 funding rounds on record, the most recent an undisclosed round of $602M announced in Dec 2025.
That round is above the $8.4M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Kymera Therapeutics Company Profile and Key Stats
Latest funding round on record: Dec 2025.
Kymera Therapeutics Funding Rounds
Kymera Therapeutics raised $102M in an undisclosed round announced in Mar 2020.
2.4 years later, a Post-IPO Equity of $150M was announced in Aug 2022.
3.3 years later, an undisclosed round of $602M was announced in Dec 2025.
Kymera Therapeutics Founders and Leadership Team
Contact details for the Kymera Therapeutics team: 1 of 1 has an email address on file.
Start 14-day free trial →Kymera Therapeutics Funding Compared to Other Biotechnology Startups
Kymera Therapeutics' latest round of $602M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Kymera Therapeutics in Biotechnology and Cambridge
Companies Similar to Kymera Therapeutics
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Altay Therapeutics is a biotech company focused on finding and discovering small molecule therapies for…
Kallyope, we believe that the gut is the gateway to our internal world. Containing millions of neurons, the…
Astrocyte Pharmaceuticals is a drug development company that helps in the recovery and well-being of brain…
Tiny Health offers a gut health test specifically designed for mothers and babies aged 0 to 3 years.…
Junevity is dedicated to using cutting-edge transcription factor medicines to combat age-related diseases.…
Arkea Bio creates technology aimed at reducing greenhouse gas (GHG) emissions in the agricultural sector.
Serán is a contract development and manufacturing organization providing a comprehensive suite of…
Precision’s goal is to provide breakthrough treatments for the one billion patients worldwide suffering from…
Enveda is a biotechnology company that utilizes AI-powered tools to explore and characterize molecules from…
Avery Therapeutics, Inc. is a company dedicated to developing tissue engineered therapeutics to treat…
Kymera Therapeutics Funding FAQs
What does Kymera Therapeutics do?
Kymera Therapeutics is a biotechnology company that specializes in the field of targeted protein degradation. It features a proprietary predictive modeling degradation platform with a novel small molecule modality to accelerate the drug discovery designed for disease-causing proteins.
How much funding has Kymera Therapeutics raised?
Kymera Therapeutics has raised $854M across 3 rounds on record. The most recent is an undisclosed round of $602M announced in Dec 2025.
When did Kymera Therapeutics last raise funding?
Kymera Therapeutics' most recent funding round on record is an undisclosed round of $602M, announced in Dec 2025.
Who is the CEO of Kymera Therapeutics?
Nello Mainolfi is listed as CEO at Kymera Therapeutics.
Where is Kymera Therapeutics headquartered?
Kymera Therapeutics is based in Cambridge, Massachusetts, United States.
How many employees does Kymera Therapeutics have?
Kymera Therapeutics is in the 101-250 employee band.
How does Kymera Therapeutics' funding compare to other Biotechnology startups?
Kymera Therapeutics' latest round of $602M is above the $8.4M median round size for Biotechnology companies on FundedIQ across 4,185 tracked companies over the last two years.
About FundedIQ's Kymera Therapeutics Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Kymera Therapeutics is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.